|
|
Vol. 14.17 – 4 September, 2025
|
|
|
|
|
|
|
|
Through EdU incorporation, genetic lineage tracing, and single cell RNA sequencing, researchers resolve the proliferation dynamics of lung fibroblasts during post-injury fibrogenesis. [Journal of Clinical Investigation]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Using both bleomycin-induced mouse models and TGF-β-stimulated alveolar epithelial cells, scientists examined the expression, activity, and pathological significance of caspase-9. [Journal of Translational Medicine]
|
|
|
|
|
|
|
|
Investigators developed a CRISPR-High Fidelity-Cas9-based therapy strategy that can effectively and specifically target KRASG12C and KRASG12D mutants, avoiding KRASWT off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity.
[Nature Communications]
|
|
|
|
|
|
Scientists found that HER2 S310F mutation contributes to third-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance, driven by the accumulation of neurotransmitter 5-hydroxytryptamine (5-HT).
[EMBO Molecular Medicine]
|
|
|
|
|
|
Investigators conducted plasma metabolomics analysis on 216 longitudinal samples from 186 NSCLC patients enrolled in the clinical trial of rezivertinib.
[Cancer Research]
|
|
|
|
|
|
An IL6R inhibitor transformed the tumor microenvironment in a murine anaplastic lymphoma kinase (ALK)+ lung adenocarcinoma model, shifting it from an immunosuppressive to a T cell–dominant status. [Cancer Immunology Research]
|
|
|
|
|
|
|
|
The authors review the epidemiological evidence linking particulate matter exposure and lung diseases including asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, pneumonia, acute respiratory distress syndrome, and lung cancer.
[Journal of Clinical Investigation]
|
|
|
|
|
|
In recent years, evidence has emerged identifying a role in the development and progression of sub-clinical interstitial lung abnormalities as well as progression and risk of exacerbation of fibrotic interstitial lung diseases. [European Respiratory Review]
|
|
|
|
|
|
|
|
The Icahn School of Medicine at Mount Sinai will award its 2025 Yergin-New International Prize for Biomedical Research to Dr. Michael Welsh of the University of Iowa for his pioneering work in cystic fibrosis, which has advanced understanding and treatment of this inherited lung disease. [The Icahn School of Medicine at Mount Sinai]
|
|
|
|
|
|
Eli Lilly and Company announced that the US FDA has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA for the first-line treatment of patients with unresectable advanced or metastatic NSCLC with a KRASG12C mutation and PD-L1 expression ≥ 50%. [Eli Lilly and Company]
|
|
|
|
|
|
|
|
October 7-10, 2025 St. Julian’s, Malta
|
|
|
|
|
|
|
|
|
|
|
Washington University in St. Louis – Washington, St. Louis, United States
|
|
|
|
|
|
|
University of Alabama at Birmingham – Birmingham, Alabama, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|
|
Ohio State University – Columbus, Ohio, United States
|
|
|
|
|
|
|
Princeton University – Princeton, New Jersey, United States
|
|
|
|
|
|